William Blair Brokers Lower Earnings Estimates for Hologic

Hologic, Inc. (NASDAQ:HOLX) – Analysts at William Blair reduced their Q1 2025 earnings per share estimates for Hologic in a report released on Monday, November 11th. William Blair analyst A. Brackmann now expects that the medical equipment provider will earn $1.00 per share for the quarter, down from their prior forecast of $1.02. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share. William Blair also issued estimates for Hologic’s FY2026 earnings at $4.62 EPS.

HOLX has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price target on shares of Hologic in a research report on Tuesday, October 15th. Evercore ISI upped their price target on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. JPMorgan Chase & Co. upped their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Leerink Partners cut their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, Stephens reaffirmed an “overweight” rating and set a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $89.91.

Hologic Stock Performance

NASDAQ HOLX opened at $77.54 on Wednesday. The company has a market capitalization of $18.01 billion, a price-to-earnings ratio of 23.29, a PEG ratio of 2.52 and a beta of 0.98. Hologic has a twelve month low of $67.59 and a twelve month high of $84.67. The stock has a fifty day simple moving average of $80.77 and a 200 day simple moving average of $78.22. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.89 earnings per share.

Hedge Funds Weigh In On Hologic

Several large investors have recently added to or reduced their stakes in the business. Paloma Partners Management Co bought a new position in Hologic in the 3rd quarter valued at about $582,000. Erste Asset Management GmbH bought a new position in Hologic in the 3rd quarter valued at about $2,223,000. Hantz Financial Services Inc. lifted its position in Hologic by 1.3% in the 3rd quarter. Hantz Financial Services Inc. now owns 105,151 shares of the medical equipment provider’s stock valued at $8,566,000 after acquiring an additional 1,357 shares in the last quarter. Public Sector Pension Investment Board lifted its position in Hologic by 13.7% in the 3rd quarter. Public Sector Pension Investment Board now owns 9,959 shares of the medical equipment provider’s stock valued at $811,000 after acquiring an additional 1,200 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Hologic by 0.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,971,617 shares of the medical equipment provider’s stock valued at $160,608,000 after buying an additional 16,057 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.